Thrombin-mediated proteolysis in neuroinflammatory disease
神经炎症疾病中凝血酶介导的蛋白水解作用
基本信息
- 批准号:8257519
- 负责人:
- 金额:$ 37.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2013-04-30
- 项目状态:已结题
- 来源:
- 关键词:AllelesAnticoagulantsAttenuatedBlindnessBlood - brain barrier anatomyBlood Coagulation FactorBlood VesselsCentral Nervous System DiseasesClinicalComparative StudyComplexDataDemyelinating DiseasesDependenceDevelopmentDiseaseEngineeringExperimental Autoimmune EncephalomyelitisFibrinFibrinogenGene TargetingGoalsHealthHemostatic AgentsInflammatoryIntegrinsInterventionKnock-outMediatingMicrogliaMolecular GeneticsMotorMultiple SclerosisMusMutationMyelin SheathNeuraxisPAR-1 ReceptorParalysedPathologyPeptide HydrolasesPharmacia brand of estropipateProcessProtease DomainProtein CProteinase-Activated ReceptorsProteolysisProthrombinRecombinantsRelapseResearchResearch PersonnelRoleSeminalSignal PathwaySignal TransductionSpecificitySystemTestingTherapeuticThrombindefined contributionin vivomouse modelmutantnovel therapeuticsprogramsprotease-activated receptor 4receptor
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this research program is to understand the role of key hemostatic factors in the progression of inflammatory demyelinating disease within the central nervous system (e.g., multiple sclerosis; MS). Since a rigorous understanding of a complex process such as inflammatory CNS disease can only be achieved in a easily-manipulated in vivo experimental setting, an important experimental asset will be gene-targeted mice with selected alterations in prothrombin or thrombin substrates. The aims of this project center on the general hypothesis that thrombin, in addition to supporting vascular integrity, is a master regulator of inflammatory processes in vivo and that multiple thrombin substrates are mechanistically tied to the progression of inflammatory demyelinating disease. The research direction is driven by strong preliminary data pointing to a seminal role of thrombin in experimental autoimmune encephalomyelitis (EAE). The overall importance of thrombin to local microglial activation and the secondary destruction of myelin sheaths that leads to loss of motor function will be established through detailed studies of neuroinflammatory disease in newly-established mice carrying either a conditional prothrombin knockout allele or expressing a mutant form of prothrombin (fIIWE) with a protease specificity switch favoring the anticoagulant substrate protein C over procoagulant substrates (Aim 1). The mechanistic contribution of distinct thrombin targets and signaling pathways will be tested through comprehensive studies of mice with constitutive or functional deficits in PAR-1, PAR-4 and fibrinogen, including mice lacking the capacity to form fibrin or lacking selected fibrin integrin receptor engagement motifs (Aim 2). Finally, the potential benefit of pharmacological intervention at the level of APC or thrombin in limiting neuroinflammatory disease will be explored using recombinant murine APC derivatives (e.g., 5A-APC) with distinct signaling and anticoagulant activities, as well as recombinant murine thrombin (fIIaWE) with a protein C-directed specificity (Aim 3). The proposed studies will provide a more detailed understanding of the crosstalk between the hemostatic and inflammatory systems in vivo, underscore the importance of thrombin in neuroinflammatory disease and illuminate potential therapeutic strategies for limiting the clinical manifestations of MS. PUBLIC HEALTH RELEVANCE: Multiple sclerosis (MS) is a common neuroinflammatory disease resulting in relapsing paralysis and vision loss. Blood-brain barrier breakdown and the local activation of hemostatic factors appear to contribute to the progression of CNS disease. The goal of this research is to use modern molecular genetics to develop a more detailed mechanistic understanding of the role of key coagulation factors in neuroinflammatory disease and identify novel therapeutic opportunities.
描述(由申请人提供):本研究项目的长期目标是了解关键止血因子在中枢神经系统内炎性脱髓鞘疾病进展中的作用(例如,多发性硬化症; MS)。由于严格理解一个复杂的过程,如炎性中枢神经系统疾病,只能在一个容易操作的体内实验环境中实现,一个重要的实验资产将是基因靶向小鼠与选定的凝血酶原或凝血酶底物的改变。该项目的目的集中在一般假设上,即凝血酶除了支持血管完整性外,还是体内炎症过程的主要调节剂,并且多种凝血酶底物与炎性脱髓鞘疾病的进展机械相关。该研究方向是由强有力的初步数据驱动的,这些数据表明凝血酶在实验性自身免疫性脑脊髓炎(EAE)中具有开创性作用。凝血酶对局部小胶质细胞活化和导致运动功能丧失的髓鞘继发性破坏的总体重要性将通过对携带条件性凝血酶原敲除等位基因或表达凝血酶原突变形式(fIIWE)的新建立小鼠的神经炎性疾病的详细研究来建立,所述凝血酶原突变形式具有有利于抗凝剂底物蛋白C而不是促凝血剂底物的蛋白酶特异性开关(目标1)。将通过对PAR-1、PAR-4和纤维蛋白原存在组成性或功能性缺陷的小鼠(包括缺乏形成纤维蛋白的能力或缺乏选定纤维蛋白整联蛋白受体结合基序的小鼠)进行综合研究,检测不同凝血酶靶点和信号传导途径的机制贡献(目的2)。最后,将使用重组鼠APC衍生物(例如,5A-APC)具有不同的信号传导和抗凝活性,以及具有蛋白C定向特异性的重组鼠凝血酶(fIIaWE)(Aim 3)。拟议的研究将提供更详细的了解体内止血和炎症系统之间的串扰,强调凝血酶在神经炎性疾病中的重要性,并阐明限制MS临床表现的潜在治疗策略。公共卫生相关性:多发性硬化症(MS)是一种常见的神经炎性疾病,导致复发性瘫痪和视力丧失。血脑屏障破坏和止血因子的局部激活似乎有助于CNS疾病的进展。这项研究的目标是利用现代分子遗传学对关键凝血因子在神经炎症性疾病中的作用进行更详细的机制理解,并确定新的治疗机会。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAY L DEGEN其他文献
JAY L DEGEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAY L DEGEN', 18)}}的其他基金
FASEB SRC on Protease in Hemostasis and Vascular Biology
FASEB SRC 关于蛋白酶在止血和血管生物学中的作用
- 批准号:
8128143 - 财政年份:2011
- 资助金额:
$ 37.13万 - 项目类别:
Thrombin-mediated proteolysis in neuroinflammatory disease
神经炎症疾病中凝血酶介导的蛋白水解作用
- 批准号:
7750332 - 财政年份:2009
- 资助金额:
$ 37.13万 - 项目类别:
Thrombin-mediated proteolysis in neuroinflammatory disease
神经炎症疾病中凝血酶介导的蛋白水解作用
- 批准号:
8077297 - 财政年份:2009
- 资助金额:
$ 37.13万 - 项目类别:
Thrombin-mediated proteolysis in neuroinflammatory disease
神经炎症疾病中凝血酶介导的蛋白水解作用
- 批准号:
7903157 - 财政年份:2009
- 资助金额:
$ 37.13万 - 项目类别:
Hemostatic Factors as Determinants of Bacterial Virulence and Host Defense.
止血因素是细菌毒力和宿主防御的决定因素。
- 批准号:
7134328 - 财政年份:2006
- 资助金额:
$ 37.13万 - 项目类别:
Hemostatic Factors as Determinants of Bacterial Virulence and Host Defense
止血因素是细菌毒力和宿主防御的决定因素
- 批准号:
7650126 - 财政年份:2006
- 资助金额:
$ 37.13万 - 项目类别:
Hemostatic Factors as Determinants of Bacterial Virulence and Host Defense.
止血因素是细菌毒力和宿主防御的决定因素。
- 批准号:
7880724 - 财政年份:2006
- 资助金额:
$ 37.13万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 37.13万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 37.13万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 37.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 37.13万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 37.13万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Studentship Programs